Summary • Kazia Therapeutics’ shares rose 18.2% to $11.24 following positive clinical trial data for Paxalisib, indicating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback